Cleavage of NK activating ligands B7-H6 and MICA/B expressed on tumour cells and the subsequent release of these soluble ligands is a strategy through which tumour cells evade NK cell-mediated immune surveillance and thus may dampen the effects of NK cell therapies [20–22]. This evidence concerns the gene NCR3LG1 and neoplasm.